FIA
TOVX icon

FNY Investment Advisers’s Theriva Biologics TOVX Stock Holding History

FNY Investment Advisers’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-28
Closed -$4K – 1133
2019
Q1 		$4K Buy
28
+19
+211% +$3.15K ﹤0.01% 539
2018
Q4 		$1K Hold
9
– – ﹤0.01% 635
2018
Q3 		$5K Hold
9
– – ﹤0.01% 622
2018
Q2 		$18K Buy
+9
New +$20.7K 0.01% 375

Other funds holding TOVX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FNY Investment Advisers's TOVX Position: Q2 2019 in Review

FNY Investment Advisers sold out of Theriva Biologics (TOVX) in Q2 2019, closing a stake of 28 shares — an estimated $4K sold.

FNY Investment Advisers first reported a position in TOVX in Q2 2018 and held it in 4 quarters. The position peaked at $18K in Q2 2018. 18 funds tracked by Wall St. Rank hold TOVX as of Q2 2019.

  • FNY Investment Advisers reported no remaining Theriva Biologics position as of Q2 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 28 Theriva Biologics shares in Q2 2019, an estimated $4K.
  • FNY Investment Advisers first reported a position in Theriva Biologics in Q2 2018 and held it in 4 quarters.
  • FNY Investment Advisers's Theriva Biologics position peaked at $18K in Q2 2018.
  • 18 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2019.

Based on FNY Investment Advisers's 13F filing for Q2 2019, filed 24 Jul 2019.